Generating evidence on the use, effectiveness, and safety of new cancer therapies is a priority for researchers, health care providers, and regulators given the rapid pace of change in cancer diagnosis and treatments. Understanding the utilization patterns and outcomes of these new treatments among cancer patients is integral for cancer treatment and research.
Historically, registry data has been considered incomplete, insufficient, or not timely enough for these broader use cases. CRStar empowers cancer centers and registry teams with processes and platform technology to address these perceptions to help extract the value embedded in registry data with the objective of making cancer registry a profit center.
